Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis

Cancer Causes Control. 2016 Nov;27(11):1325-1332. doi: 10.1007/s10552-016-0810-x. Epub 2016 Sep 28.

Abstract

Purpose: Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The association between endocrine therapy and common pelvic floor disorders including urinary incontinence has rarely been evaluated. We examined urogenital and sexual side effects among women with a breast cancer diagnosis, comparing endocrine therapy users to nonusers.

Methods: Urogenital and sexual symptoms were self-reported during the enrollment interview within the University of North Carolina Cancer Survivorship Cohort. Tumor characteristics and endocrine therapy use were collected from medical and prescription records. We calculated multivariable prevalence ratios (PR) and 95 % confidence intervals (CI) for the association of endocrine therapy (versus no endocrine therapy) and urinary incontinence, overall and by therapy type (tamoxifen or aromatase inhibitors). PROMIS Sexual Function and Satisfaction domain scores were compared across endocrine therapy groups.

Results: Among the 548 women with a breast cancer diagnosis, 49 % received endocrine therapy. Overall, 18 % of women reported urinary incontinence symptoms. We observed no association between urinary incontinence and endocrine therapy use overall (PR = 0.97; 95 % CI 0.67, 1.43), tamoxifen (PR = 1.20; 95 % CI 0.74, 1.96), or aromatase inhibitors (PR = 0.89; 95 % CI 0.55, 1.42), compared to no use. Approximately 55 % of women were sexually active. Sexual function scores did not vary according to endocrine therapy use, although urinary incontinence was associated with lower satisfaction scores (p = 0.05).

Conclusions: Our findings demonstrate a high prevalence of urinary incontinence after breast cancer diagnosis similar to the overall prevalence in older U.S. women, and this did not vary strongly according to use of endocrine therapy.

Keywords: Cancer survivors; Endocrine therapy; Patient-reported outcomes; Sexual function; Urinary incontinence.

MeSH terms

  • Aged
  • Aromatase Inhibitors / adverse effects*
  • Aromatase Inhibitors / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Middle Aged
  • Prevalence
  • Sexual Dysfunction, Physiological / chemically induced*
  • Sexual Dysfunction, Physiological / epidemiology
  • Tamoxifen / adverse effects*
  • Tamoxifen / therapeutic use
  • Urinary Incontinence / chemically induced*
  • Urinary Incontinence / epidemiology

Substances

  • Aromatase Inhibitors
  • Tamoxifen